A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis
Authors
Keywords
-
Journal
ONCOGENE
Volume 35, Issue 43, Pages 5608-5618
Publisher
Springer Nature
Online
2016-01-25
DOI
10.1038/onc.2015.516
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity
- (2015) Gerald J Prud'homme et al. Oncotarget
- A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors
- (2014) Amita Patnaik et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors
- (2014) Colin D. Weekes et al. INVESTIGATIONAL NEW DRUGS
- Immunohistological Insight into the Correlation between Neuropilin-1 and Epithelial-Mesenchymal Transition Markers in Epithelial Ovarian Cancer
- (2014) Sirin A. I. Adham et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- MUC1 Enhances Tumor Progression and Contributes Toward Immunosuppression in a Mouse Model of Spontaneous Pancreatic Adenocarcinoma
- (2014) T. L. Tinder et al. JOURNAL OF IMMUNOLOGY
- The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer
- (2013) Jennifer M. Curry et al. JOURNAL OF SURGICAL ONCOLOGY
- MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes
- (2013) S Nath et al. Oncogenesis
- Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors
- (2012) Y. Xin et al. CLINICAL CANCER RESEARCH
- Cancer Stem Cells and Novel Targets for Antitumor Strategies
- (2012) Gerald J. Prud’homme CURRENT PHARMACEUTICAL DESIGN
- Neuropilins: expression and roles in the epithelium
- (2012) Jonathan R. L. Wild et al. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
- Autocrine VEGF–VEGFR2–Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth
- (2012) Petra Hamerlik et al. JOURNAL OF EXPERIMENTAL MEDICINE
- MUC1 regulates PDGFA expression during pancreatic cancer progression
- (2012) M Sahraei et al. ONCOGENE
- Pancreatic Ductal Adenocarcinoma Mice Lacking Mucin 1 Have a Profound Defect in Tumor Growth and Metastasis
- (2011) D. M. Besmer et al. CANCER RESEARCH
- A vascular niche and a VEGF–Nrp1 loop regulate the initiation and stemness of skin tumours
- (2011) Benjamin Beck et al. NATURE
- Mucin 1 enhances the tumor angiogenic response by activation of the AKT signaling pathway
- (2011) J K Woo et al. ONCOGENE
- Zebrafish Model: Worth Considering in Defining Tumor Angiogenesis
- (2011) Karni S. Moshal et al. TRENDS IN CARDIOVASCULAR MEDICINE
- Discriminating Different Cancer Cells Using a Zebrafish in Vivo Assay
- (2011) Karni S. Moshal et al. Cancers
- ERβ Impedes Prostate Cancer EMT by Destabilizing HIF-1α and Inhibiting VEGF-Mediated Snail Nuclear Localization: Implications for Gleason Grading
- (2010) Paul Mak et al. CANCER CELL
- MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition
- (2010) L D Roy et al. ONCOGENE
- Neuropilins in Tumor Biology
- (2009) A. Bagri et al. CLINICAL CANCER RESEARCH
- Neuropilins: structure, function and role in disease
- (2008) Caroline Pellet-Many et al. BIOCHEMICAL JOURNAL
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started